UK Markets closed

Laboratorios Farmaceuticos Rovi, S.A. (0ILL.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
30.90-0.30 (-0.96%)
At close: 1:39PM GMT

Laboratorios Farmaceuticos Rovi, S.A.

Calle JuliAn Camarillo, 35

Full-time employees1,338

Key executives

NameTitlePayExercisedYear born
Mr. Juan López-Belmonte EncinaCEO & Director481kN/AN/A
Mr. Iván López-Belmonte EncinaFirst Deputy Chairman & Head of Corp. Devel.356kN/AN/A
Mr. Javier López-Belmonte EncinaSecond Deputy Chairman & CFO357kN/AN/A
Ms. Mercedes Benítez del Castillo SánchezLegal Department Mang.N/AN/AN/A
Mr. Fernando Martínez MoralesDirector of SalesN/AN/AN/A
Ms. Rosario Perucha PérezMarketing Mang.N/AN/AN/A
Mr. Francisco Javier Angulo GarcíaHR Mang.N/AN/AN/A
Mr. Gabriel Núñez FernándezSec.N/AN/AN/A
Mr. Ignacio Zarzalejos ToledanoDeputy Sec.N/AN/AN/A
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company also distributes other products that are licensed from other laboratories. Its principal products include Hibor, a low-molecular-weight heparin to prevent thromboembolic disease; Enoxaparin biosimilar, a low-molecular-weight heparin; Neparvis for the treatment of symptomatic chronic heart failure with reduced ejection in adult patients; Absorcol, Vytorin, and Orvatez to diet in patients with hypercholesterolemia; Hirobriz Breezhaler and Ulunar Breezhaler that are long-acting bronchodilators for the maintenance treatment of chronic obstructive pulmonary diseases; Volutsa for the treatment of moderate to severe storage systems symptoms and voiding symptoms associated with benign prostatic hyperplasia in men who are not responding adequately to monotherapy treatment; and Medikinet and Medicebrán that are prescription medicines for treatment of attention deficit hyperactivity disorder in children and adolescents. The company also markets various hospital products for imaging diagnosis, such as Iomeron and Iopamiro for computed tomography and intervention; Multihance and Prohance for magnetic resonance imaging; Sonovue for ultrasounds; and EmpowerCTA+, EmpowerMR, and CT Exprès that are contrast injection systems and compatible disposable material. In addition, it provides non-prescription pharmaceutical products; and contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets. The company serves wholesalers, doctors, nursing staff, pharmacists, and patients. It has a collaboration with Moderna, Inc. for manufacturing COVID-19 vaccine candidate. Laboratorios Farmaceuticos Rovi, S.A. was founded in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.

Corporate governance

Laboratorios Farmaceuticos Rovi, S.A.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.